Evidence map›Paper›PMID 33609255›Full record

ReviewClinical reviews in allergy & immunology2023

A Review of Persistent Post-COVID Syndrome (PPCS).

Bryan Oronsky, Christopher Larson, Terese C Hammond, Arnold Oronsky, Santosh Kesari, Michelle Lybeck, Tony R Reid

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
198citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

198 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

138 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bryan OronskyEpicentRx Inc, La Jolla, 11099 North Torrey Pines Road, Suite 160, La Jolla, CA, 92037, USA. boronsky@epicentrx.com.ORCID http://orcid.org/0000-0002-3940-6329
Christopher LarsonEpicentRx Inc, La Jolla, 11099 North Torrey Pines Road, Suite 160, La Jolla, CA, 92037, USA.
Terese C HammondProvidence St. John's Health Center, Santa Monica, CA, USA.
Arnold OronskyInterWest Partners, Los Altos, CA, USA.
Santosh KesariProvidence St. John's Health Center, Santa Monica, CA, USA.
Michelle LybeckEpicentRx Inc, La Jolla, 11099 North Torrey Pines Road, Suite 160, La Jolla, CA, 92037, USA.
Tony R ReidEpicentRx Inc, La Jolla, 11099 North Torrey Pines Road, Suite 160, La Jolla, CA, 92037, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Persistent post-COVID syndrome, also referred to as long COVID, is a pathologic entity, which involves persistent physical, medical, and cognitive sequelae following COVID-19, including persistent immunosuppression as well as pulmonary, cardiac, and vascular fibrosis. Pathologic fibrosis of organs and vasculature leads to increased mortality and severely worsened quality of life. Inhibiting transforming growth factor beta (TGF-β), an immuno- and a fibrosis modulator, may attenuate these post-COVID sequelae. Current preclinical and clinical efforts are centered on the mechanisms and manifestations of COVID-19 and its presymptomatic and prodromal periods; by comparison, the postdrome, which occurs in the aftermath of COVID-19, which we refer to as persistent post-COVID-syndrome, has received little attention. Potential long-term effects from post-COVID syndrome will assume increasing importance as a surge of treated patients are discharged from the hospital, placing a burden on healthcare systems, patients' families, and society in general to care for these medically devastated COVID-19 survivors. This review explores underlying mechanisms and possible manifestations of persistent post-COVID syndrome, and presents a framework of strategies for the diagnosis and management of patients with suspected or confirmed persistent post-COVID syndrome.

Indexed as

COVID-19Post-Acute COVID-19 SyndromeDisease ProgressionHumansImmunosuppression TherapyQuality of LifeCOVID-19ImmunologySARS-CoV-2TGF-β

Identifiers

PMID33609255
PMCPMC7896544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.